Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Enrolling by invitation · NCT06896110 · Registry updated 2025-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 4, epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Enrolling by invitation | Phase 1 | 2025-06-26 | NCT06896110 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Andrew P. Groves | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Holden Comprehensive Cancer Center | Iowa City | United States | 6 |